Search

Abstract Background Radiotherapy (RT) is the chief nonsurgical method to control malignant tumors. RT has advanced in both methodological and biological aspects over the past few decades. Though RT is a momentous adjuvant non-invasive technique, it leaves behind some unsympathetic effects. Research is going on to surmount these pessimistic sides of RT. Methods We made a mini review of recent articles from the period of 2000 to 2017 regarding radiotherapy and its side effects in various types of cancers. The literature review was done by searching in PUBMED, MEDLINE, and SCOPUS. Results Here, we spotlight the physiological and genetic risks associated with the cancer patients undergoing RT. We illustrated the course of RT in most prevalent cancers tailored with dosage distribution. Radiation-induced mutation in the patients undergoing RT has been shown with evidence. Further, the major drawbacks like the development of radiation resistance in cancerous cells and secondary malignancies have been discussed. The problems associated with radiation dosage in terms of infertility and rejuvenation of reproductive cells has also been discussed. Finally, we discussed the latest treatment stratagem of RT in cancer. Conclusion Cancer treatment will not be accomplished devoid of radiotherapy. But we can brace RT using radiosensitizers and ayurvedic radioprotectors.

Drug studies on Rett syndrome (RTT) have drastically increased over the past few decades. This review aims to provide master data on bench-to-bedside drug studies involving RTT. A comprehensive literature review was performed by searching in PUBMED, MEDLINE and Google Scholar, international, national and regional clinical trial registries and pharmaceutical companies using the keywords "Rett syndrome treatment and/or drug or compound or molecule". Seventy drugs were investigated in non-clinical (N = 65 animal/cell line-based studies; N = 5 iPSC-based study) and clinical trials (N = 34) for ameliorating the symptoms of RTT. Though there is good progress in both clinical and non-clinical studies, none of these drugs entered phase III/IV for being launched as a therapeutic agent for RTT.

The Glass syndrome is a rare genetic disorder that is associated with a multisystem disorder due to a SATB2 gene mutation. The intellectual development delay and the delay in speech are the predominant characteristics of the disorder. The reports on Glass syndrome are very few and have not been reported in India. In the present study, we report the Glass syndrome disorder in an Indian mother and her child, both affected by the same likely pathogenic mutation c.1741-2A>C intronic variant at intron 11 of the SATB2 gene. The mutation was observed as a heterozygous and autosomal dominant missense mutation through focused exome sequencing analysis. The variant identified has not been observed in the general population, and the clinical features like cleft palate, speech delay, and intellectual delay match the causative mutation. The present study is novel in exhibiting the intronic variant and identifying Glass syndrome in the Indian population. [ABSTRACT FROM AUTHOR]